Literature DB >> 11574820

Colon epithelial cellular protein induces oral tolerance in the experimental model of colitis by trinitrobenzene sulfonic acid.

A Dasgupta1, K Ramaswamy, J Giraldo, M Taniguchi, P S Amenta, K M Das.   

Abstract

Rectal administration of trinitrobenzene sulfonic acid (TNBS) produces chronic colitis in experimental animals. However, the role of epithelial cellular protein(s) in this model is unknown. We examined whether oral tolerance can be induced in this model with colon epithelial cell proteins and whether it is organ specific. Rats were fed five times with extracts of LS-180 human colon cancer cells or HT 1080 human fibroblast cells. Syngeneic normal rat colon or small intestinal extracts were fed to separate groups of rats. After oral feedings, each rat received TNBS by enema. Rats were killed 15 days later, and the following were measured: gross and histologic disease score, weight, thickness, and myeloperoxidase values of colon and serum interferon-gamma (IFN-gamma) and transforming growth factor-beta (TGF-beta) levels. Rectal TNBS alone produced severe colitis with a 26% mortality rate. Rats fed LS-180 or rat colon extract before TNBS enema were protected, as evidenced by reductions in mortality rate, disease scores, and myeloperoxidase values. However, rats fed HT 1080 or small intestine extract lacked such protection. To examine the possible mechanism of the oral tolerance, T lymphocytes from mesenteric lymph nodes and spleen of LS-180 extract-fed rats were passively transferred to naive rats, and this was followed by TNBS enema. These rats showed clear protection. Protected animals had low IFN-gamma and high TGF-beta levels. This study demonstrates that cellular protein(s) from human colon epithelial cells, but not from human fibroblasts, can induce oral tolerance in experimental colitis. This oral tolerance is mediated by primed mesenteric and splenic T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11574820     DOI: 10.1067/mlc.2001.118221

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  6 in total

1.  Effects of appendectomy and oral tolerance on dextran sulfate sodium colitis.

Authors:  Min Yue; Zhe Shen; Chao-Hui Yu; Hua Ye; Yue-Fang Ye; You-Ming Li
Journal:  World J Gastroenterol       Date:  2011-05-21       Impact factor: 5.742

2.  Oral administration of Alequel, a mixture of autologous colon-extracted proteins for the treatment of Crohn's disease.

Authors:  Eran Israeli; Yaron Ilan
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

3.  Oral immune regulation using colitis extracted proteins for treatment of Crohn's disease: results of a phase I clinical trial.

Authors:  Eran Israeli; Eran Goldin; Oren Shibolet; Athalia Klein; Nilla Hemed; Dean Engelhardt; Elazar Rabbani; Yaron Ilan
Journal:  World J Gastroenterol       Date:  2005-05-28       Impact factor: 5.742

4.  The protective effect of oral colitis-derived proteins in a murine model of inflammatory bowel disease is associated with an increase in gammadelta T cells in large intestinal mucosa.

Authors:  Yuefang Ye; Xi Jin; Min Yue; Shaohua Chen; Chaohui Yu; Youming Li
Journal:  Int J Colorectal Dis       Date:  2010-06-23       Impact factor: 2.571

5.  Oral mixture of autologous colon-extracted proteins for the Crohn's disease: A double-blind trial.

Authors:  Eran Israeli; Ehud Zigmond; Gadi Lalazar; Athalia Klein; Nilla Hemed; Eran Goldin; Yaron Ilan
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

6.  Hsp65-Producing Lactococcus lactis Prevents Inflammatory Intestinal Disease in Mice by IL-10- and TLR2-Dependent Pathways.

Authors:  Ana Cristina Gomes-Santos; Rafael Pires de Oliveira; Thaís Garcias Moreira; Archimedes Barbosa Castro-Junior; Bernardo Coelho Horta; Luísa Lemos; Leonardo Augusto de Almeida; Rafael Machado Rezende; Denise Carmona Cara; Sérgio Costa Oliveira; Vasco Ariston Carvalho Azevedo; Anderson Miyoshi; Ana Maria Caetano Faria
Journal:  Front Immunol       Date:  2017-01-30       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.